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Edited by Judit Ova´diAbstract Eﬀect of 5–100 lM epigallocatechin gallate (EGCG)
on hepatic glucose 6-phosphatase (G6Pase) system was investi-
gated. EGCG inhibited G6Pase in intact but not in permeabili-
zed rat liver microsomes, suggesting the interference with the
transport. However, EGCG did not hinder microsomal glucose
6-phosphate (G6P) uptake. Instead, it increased the accumula-
tion of radioactivity after the addition of [14C]G6P, presumably
due to a slower release of [14C]glucose, the product of luminal
hydrolysis. Indeed, EGCG was found to inhibit microsomal glu-
cose eﬄux. Since G6Pase activity is depressed by glucose in a
concentration-dependent manner, we concluded that EGCG
inhibits G6Pase through an elevated luminal glucose level.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The various beneﬁcial health eﬀects of green tea consump-
tion have received signiﬁcant scientiﬁc attention recently [1].
Extensive investigations revealed that most of these eﬀects
can be attributed to polyphenolic compounds, which have long
been known to possess widespread biological functions [2].
Green tea is especially rich in polyphenols; they represent
30% of the leaf dry matter [3]. Major polyphenols in the fresh
tea leaves are ﬂavanol (catechin) monomers, among which epi-
gallocatechin, epicatechin, and their gallic esters are particu-
larly abundant [4].
The best studied eﬀects of epigallocatechin gallate (EGCG)
are those related to the prevention of cancer and cardiovascu-
lar disease. In addition, several studies demonstrated its anti-Abbreviations: EGCG, epigallocatechin gallate; G6Pase, glucose 6-
phosphatase; G6P, glucose 6-phosphate; ER, endoplasmic reticulum;
G6PT, glucose 6-phosphate translocase; H6PDH, hexose 6-phosphate
dehydrogenase; CHA, chlorogenic acid; GCG, gallocatechin gallate;
ECG, epicatechin gallate; PG, propyl gallate; MOPS, 4-morpholine-
propanesulfonic acid; 11b-HSDH1, 11b-hydroxysteroid dehydroge-
nase type 1; ME, metyrapone
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doi:10.1016/j.febslet.2007.03.045obesity and anti-diabetic eﬀects [5]. EGCG decreases body
weight and fat mass, inﬂuences adipocyte diﬀerentiation and
proliferation, hormone levels and intermediary metabolism
[6]. It was also reported to reduce blood glucose level by
decreasing hepatic glucose production [7–9] through down-reg-
ulation of phosphoenolpyruvate carboxykinase and glucose
6-phosphatase (G6Pase) at transcriptional level [9–11].
G6Pase catalyzes the ﬁnal step of hepatic glucose production,
i.e. the hydrolysis of glucose 6-phosphate (G6P) derived either
from glycogen breakdown or from gluconeogenesis. The active
site of G6Pase is localized in the lumen of the endoplasmic retic-
ulum (ER); therefore, transporter proteins are needed to allow
the entry of G6P into, as well as the exit of glucose and phos-
phate from this compartment [12]. Glucose transport across
the ER membrane was shown to be a high-capacity bidirec-
tional facilitated uniport [13], though the glucose transporter
protein of the ER has not been identiﬁed. Similarly to several
other luminal enzymes, G6Pase has higher activity and lower
speciﬁcity if the ER membrane is permeabilized. This phenom-
enon is referred to as latency and indicates that the transmem-
brane ﬂuxes – presumably both the G6P uptake and the glucose
release – are rate-limiting for the overall process [12].
G6Pase as well as hexose 6-phosphate dehydrogenase
(H6PDH), the other G6P consuming enzyme in the ER lumen
are provided with substrate by the G6P translocase (G6PT)
that catalyzes the selective transport of G6P across the ER
membrane [14]. Chlorogenic acid (CHA) and its derivatives
(e.g. S3483) are potent inhibitors of G6PT [15]. Accordingly,
they increase the latency of G6Pase and H6PDH by reducing
their activity in intact microsomes or in the intact ER in situ.
CHA and curcumin were shown to induce glioma cell death
through the inhibition or suppressed expression of G6PT,
respectively [16,17]. The interesting observation that this eﬀect
can be mimicked by EGCG inspired the hypothesis that CHA
and EGCG can be linked to a common intracellular target,
namely G6PT [17]. It also implies that EGCG might inhibit
the hepatic G6Pase system directly, in addition to the long-
term transcriptional eﬀect.
In the present work, we investigated the potential eﬀect of
EGCG and other green tea catechins on G6Pase and related
transport activities in rat liver microsomes. Our aim was to re-
veal whether a direct inhibition of the hepatic G6Pase system
can contribute to the metabolic eﬀects of tea ﬂavanols. Our re-
sults show that EGCG reduces the activity of G6Pase through
the inhibition of glucose eﬄux from the ER lumen.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
G6P, glucose, EGCG, gallocatechin gallate (GCG), epicatechin gal-
late (ECG), propyl gallate (PG), alamethicin, 4-morpholinepropane-
sulfonic acid (MOPS) were purchased from Sigma Chemical Co.
[14C]G6P and [14C]glucose were obtained from MP Biomedicals.
S3483 was kindly supplied by Aventis Pharma. All other reagents were
of analytical grade.2.2. Preparation of rat liver microsomal vesicles
Microsomes were prepared from livers of overnight fasted male Wis-
tar rats (180–230 g), using fractional centrifugation [18]. The ER vesi-
cles were washed and re-suspended in MOPS–KCl buﬀer (100 mM
KCl, 20 mM NaCl, 3 mM MgCl2, 20 mM MOPS; pH 7.2) then imme-
diately frozen in liquid nitrogen and kept in liquid nitrogen until use
(within 6 months). The protein concentration in microsomal samples
was determined using the method of Lowry et al. [19] with bovine ser-
um albumin as a standard.
Purity of the microsomes was assessed by a marker-enzyme analysis
as described earlier [20]. The integrity of the microsomal membranes
was ascertained by using the mannose-6-phosphatase assay [21], which
showed a latency greater than 95%.
2.3. G6Pase activity measurements and calculation of the latency
The microsomes (1 mg protein/ml) were incubated in MOPS–KCl
buﬀer containing 5 mM G6P for 3 min at 37 C to determine the rate
of G6P hydrolysis. Vanadate (1 mM), S3483 (50 lM), PG (100 lM) or
the investigated tea ﬂavanols (at the indicated concentrations) were
added to the microsomes 2–3 min before starting the reaction with
G6P. Parallel incubations were set up containing intact microsomes
and microsomes permeabilized with the pore-forming antibiotic ala-
methicin (0.1 mg/mg microsomal protein) [22]. The initial and ﬁnal
concentrations of inorganic phosphate (Pi) were measured in the sam-
ples using the sensitive assay of Chen et al. [23] with slight modiﬁca-
tion. The reagent mixture, which was prepared daily, contained 1
part of 10% ascorbic acid, 2 parts of 10% SDS and 6 parts of 0.42%
ammonium molybdate Æ 4H2O in 1 N H2SO4. One milliliter of reagent
was added to 100 ll sample and after 20 min at 46 C the optical den-
sity was measured at 820 nm wavelength against a blank containing
1 ml reagent and 100 ll MOPS–KCl buﬀer. G6Pase activity was calcu-
lated as the amount of inorganic phosphate produced in 1 min by 1 mg
microsomal protein. To determine the latency quantitatively, the diﬀer-
ence between the activities measured in intact and permeabilized
microsomes was expressed as the percentage of the latter [12].
2.4. Rapid ﬁltration transport assay
G6P inﬂux and glucose eﬄux were studied at 20 C, using a rapid
ﬁltration method with radiolabeled tracers. In both cases, the micro-
some-associated radioactivity was measured after rapid ﬁltering of
the samples (100 ll volume) through cellulose acetate/nitrate ﬁlter
membranes (MF-Millipore; 25 mm diameter; 0.22 lm pore size). The
ﬁlters were immediately washed with 2.5 ml of ice-cold MOPS–KCl
buﬀer and counted for radioactivity in a liquid scintillation counter.
The ﬁltration and washing procedure took about 10 s. In order to dis-
tinguish the intravesicular and membrane-bound radioactivity, parallel
measurements were carried out in intact and alamethicin-permeabili-
zed [24] microsomes. Alamethicin-treatment did not alter the recovery
of microsomal proteins on the ﬁlters, indicating that the vesicular
structure of microsomes was maintained. The alamethicin-releasable
portion of radioactivity was regarded as intravesicular.
For G6P uptake measurements, the microsomes (2 mg protein/ml)
were incubated in MOPS–KCl buﬀer containing 1 mM G6P and
600000 cpm [14C]G6P in a ﬁnal volume of 140 ll and the samples were
ﬁltered after 30 s incubation. S3483 (50 lM), EGCG (50 or 100 lM)
and vanadate (1 mM) were administered 2–3 min before the addition
of G6P and the radioactive tracer. For glucose release measurements,
the microsomes (4 mg protein/ml) were loaded for 1 h in 140 ll
MOPS–KCl buﬀer containing 5 mM glucose and 300000 cpm [14C]glu-
cose. EGCG (0, 50 or 100 lM) was added in a small volume of MOPS–
KCl buﬀer to the samples 2–3 min before ﬁltering. Glucose release oc-
curred when the vesicles were washed on the ﬁlters, so the wash buﬀer
contained EGCG at the same concentration as the corresponding
sample.2.5. Measurement of metyrapone-dependent accumulation of
radioactivity upon [14C]G6P addition
Inward G6P transport was also detected using the method described
by Gerin and Van Schaftingen [25] with minor modiﬁcations. Micro-
somes (8 mg protein/ml ﬁnal concentration) were incubated in
MOPS–KCl buﬀer containing 1 mM metyrapone, 10 lM G6P, and
300000 cpm [14C]G6P in a ﬁnal volume of 50 ll. S3483 (50 lM) and
EGCG (50 or 100 lM) were administered 2–3 min before the addition
of G6P and the radioactive tracer. Metyrapone was omitted from the
samples where indicated. After 6 min incubation at 20 C, the samples
were mixed with 500 ll of ice-cold MOPS–KCl buﬀer, and rapidly ﬁl-
tered through cellulose acetate/nitrate ﬁlter membranes (MF-Milli-
pore; 25 mm diameter; 0.22 lm pore size), which were immediately
washed with 2.5 ml of ice-cold MOPS–KCl buﬀer. Finally, the ﬁlter-re-
tained radioactivity was determined with a liquid scintillation counter.
2.6. Statistical analysis
Results are expressed as means ± S.E.M or means ± S.D. Results
were compared using the Student’s two-tailed t-test: P < 0.05 was con-
sidered statistically signiﬁcant.3. Results and discussion
3.1. Inhibition of G6Pase activity by EGCG
The hypothesis that EGCG can inhibit the hepatic G6Pase
system directly was ﬁrst tested by enzyme activity measure-
ments in intact and permeabilized liver microsomes. The max-
imal G6Pase activity of liver microsomes can only be detected
when the membrane barrier is eliminated. This can be achieved
without destroying the vesicular structure by permeabilizing
the microsomal membrane with a pore-forming antibiotic, ala-
methicin [22,24]. In our experiments, the activity measured in
intact microsomes was only about 65% of the one observed
after alamethicin-treatment, i.e. the latency was around 35%
(Table 1). Inhibitors of G6P transport (e.g. S3483 [15]) only de-
press G6Pase activity in intact microsomes, thus increase the
latency (Table 1). In contrast, inhibitors of G6Pase enzyme
(e.g. vanadate [26]) reduce the activity both in intact and
permeabilized microsomes; and usually decrease the latency
because the transport is no longer rate-limiting when the
enzyme itself works slower (Table 1). The metabolic eﬀects
of green tea ﬂavanols – the insulin-like eﬀects on hepatic glu-
cose production in particular – were studied in vitro in the con-
centration range of 10–100 lM and they were found to be most
pronounced at 100 lM level [9,11]. Therefore, the selected tea
ﬂavanols were studied in similar conditions in our experiments.
EGCG and its isomer GCG were found to increase the latency
of G6Pase, because their inhibitory eﬀect was greater in intact
than in permeabilized microsomes. ECG acted similarly but
less eﬃciently, while PG, a non-catechin gallate was apparently
ineﬀective (Table 1). The comparison of these agents suggests
that the core catechin structure is essential for the eﬀect, which
is enhanced by the gallo moiety and also by the gallate group,
though to a lesser extent.
The observed inhibitory eﬀect of the main tea catechin,
EGCG was further studied by determining its concentration-
dependence. As it is also shown in Table 1, the higher concen-
trations of EGCG moderately aﬀected G6Pase activity in the
permeabilized microsomes (Fig. 1), which must be due to a
week direct interaction with the enzyme protein; nevertheless
this eﬀect was statistically not signiﬁcant (P = 0.0894 for
100 lMEGCG vs. control). In contrast, the increasing concen-
tration of EGCG caused an increasing inhibition of G6Pase
activity in the intact microsomes (Fig. 1). The dissociation of
Table 1
Inhibition of G6Pase activity in intact and permeabilized microsomes
Inhibitor G6Pase activity in intact
microsomes (nmol/min/mg protein)
G6Pase activity in permeabilized
microsomes (nmol/min/mg protein)
G6Pase latency (%)
None 80.2 ± 4.3 123.6 ± 8.1 35.1
100 lM GCG 42.3 ± 3.8** 100.6 ± 13.4* 57.9
100 lM ECG 60.0 ± 6.7** 107.0 ± 11.0 43.9
100 lM EGCG 47.5 ± 4.2** 111.0 ± 9.5 57.2
100 lM PG 74.8 ± 7.5 119.3 ± 10.4 37.3
50 lM S3483 6.0 ± 1.1** 118.5 ± 7.3 94.9
1 mM vanadate 1.7 ± 0.5** 1.9 ± 0.8** 7.3
Enzyme activity was measured at 5 mMG6P concentration in intact and alamethicin-permeabilized liver microsomes (1 mg protein/ml). The putative
inhibitors were administered 2–3 min prior to the substrate. Latency represents the diﬀerence between G6Pase activities measured in intact and
permeabilized microsomes expressed as the percentage of the latter. Data are shown as means ± S.D., n = 4, *P < 0.05, **P < 0.01 vs. control values
(None).
Fig. 1. Inhibition of G6Pase activity in intact and permeabilized
microsomes. Enzyme activity was measured at 5 mM G6P concentra-
tion in intact (d) and alamethicin-permeabilized (s) liver microsomes
(1 mg protein/ml). EGCG was administered at the indicated concen-
trations 2–3 min prior to the substrate. Latency of G6Pase activity as a
function of EGCG concentration is shown in the inset. Data are shown
as means ± S.E.M. from four experiments.
Fig. 2. Eﬀect of EGCG on microsomal G6P uptake. Liver microsomes
(2 mg protein/ml) were pretreated for 2–3 min with 50 lM EGCG,
100 lMEGCG, 50 lM S3483, 1 mM vanadate or none (control). Then
G6P was added together with radiolabeled [14C]G6P tracer at 1 mM
ﬁnal concentration, and after 30 s the amount of intraluminal G6P was
determined in 100 ll samples using rapid ﬁltration technique as
described in Section 2. Data are shown as means + S.E.M., n = 4,
*P < 0.05, **P < 0.01 vs. control.
M. Csala et al. / FEBS Letters 581 (2007) 1693–1698 1695the activities measured in intact and permeabilized microsomes
is also reﬂected by the gradually growing latency from 35% to
nearly 60% (Fig. 1, inset). This observation strongly suggests
that EGCG aﬀects the G6Pase system through inhibiting one
of the transport processes involved.
3.2. Eﬀect of EGCG on the uptake of G6P into microsomes
Since the results of the enzyme activity measurements indi-
cated that the target of EGCG is a transport associated to
G6Pase activity, we investigated the eﬀect of this ﬂavanol on
microsomal G6P inﬂux using a direct transport assay. The
accumulation of radioactivity in the microsomal vesicles was
detected using rapid ﬁltration after addition of G6P with
radioactive tracer. Inhibition of G6Pase with vanadate reduced
the apparent G6P uptake remarkably (Fig. 2), which demon-
strates that a signiﬁcant part of the luminal radioactivity can
be attributed to glucose produced locally. It also indicates that
a considerable amount of glucose is entrapped in the micro-
somal lumen during the sort time (30 s) of this incubation.
In fact, the measurement of pure G6P transport would re-
quire the inhibition of G6Pase. Therefore, the possible eﬀect
of EGCG on G6P uptake could be best assessed in the pres-ence of vanadate but the two compounds are incompatible,
i.e. vanadate oxidizes EGCG. Still, the experimental system
(without vanadate) is suitable to detect the inhibition of G6P
uptake, which is well proven by the nearly abolished accumu-
lation of radioactivity in the presence of the known G6PT
inhibitor, S3483 (Fig. 2). In contrast to S3483, EGCG was
found to stimulate rather than inhibit the apparent G6P up-
take (Fig. 2). It is theoretically possible, yet unlikely, that
EGCG really enhances the inﬂux of G6P. The stimulation of
such a facilitated passive diﬀusion is seldom observed. The in-
creased luminal accumulation of radioactivity in the presence
of EGCG in our experiments is due presumably to a hindered
glucose eﬄux.
To minimize the interference of glucose production without
vanadate administration, G6P uptake was also studied in
microsomes where the luminal metabolism of G6P was di-
verted from G6Pase [25]. This was achieved by activating
H6PDH that binds G6P with high aﬃnity and converts it to
6-phosphogluconate as long as luminal NADP+ is available.
The luminal NADP+ generation can be fuelled by metyrapone
Fig. 4. Inhibition of glucose release from microsomal vesicles by
EGCG. Liver microsomes (4 mg protein/ml) were loaded with 5 mM
glucose and radio-labeled [14C]glucose tracer by incubation for 1 h at
room temperature. Then 50 lM EGCG, 100 lM EGCG or none
(control) was administered and 100 ll samples were ﬁltered and
washed to determine the amount of glucose retained in the vesicles as
described in Section 2. Data are shown as means + S.E.M., n = 6,
*P < 0.05, **P < 0.01 vs. control.
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by 11b-hydroxysteroid dehydrogenase type 1 (11bHSDH1)
[12]. The presence of ME greatly enhances the luminal accu-
mulation of radioactivity after the addition of G6P with radi-
olabeled tracer (Fig. 3, control vs. without ME). It indicates
that the majority of luminal radioactivity in these conditions
can be attributed to 6-phosphogluconate, which does not have
eﬃcient membrane transport to leave the microsomes as re-
ported earlier [25]. In contrast to S3483, EGCG did not aﬀect
the accumulation of radioactivity in the microsomal lumen
(Fig. 3), which supports that the target of this tea catechin is
not the G6PT.
3.3. Inhibition of microsomal glucose release by EGCG
The above results strongly suggest that EGCG aﬀects
G6Pase system by inhibiting glucose eﬄux from the micro-
somal lumen. Although the glucose transporter of the ER
has not been identiﬁed at molecular level, several observations
suggest the existence of a protein-mediated transport [12]. The
assumption that EGCG inhibits this yet unidentiﬁed trans-
porter was tested in direct transport measurements. Preloaded
microsomal vesicles retained signiﬁcantly more glucose when
washed with a buﬀer containing EGCG, as compared to the
control (Fig. 4). The relatively high rate of glucose eﬄux does
not allow the precise determination of the initial luminal glu-
cose content with rapid ﬁltration. However, it can be estimated
to be around 18 nmol/mg protein assuming that the intravesic-
ular water space (3.6 ll/mg protein) of rat liver microsomes
reported earlier [27] completely equilibrated with the
extravesicular ﬂuid containing 5 mM glucose during the 1 h
long preincubation period. Therefore, it can be ﬁgured that
the control microsomal vesicles and those treated with
100 lM EGCG released 9.90 ± 0.86 and 3.37 ± 2.27 nmol/mg
protein glucose, respectively, i.e. glucose eﬄux was nearly
three-times slower in the presence EGCG. These results pro-Fig. 3. EGCG fails to aﬀect metyrapone-induced accumulation of
radio-labeled G6P metabolites. Liver microsomes (8 mg protein/ml)
were pre-incubated with or without 1 mM metyrapone for 10 min. The
metyrapone-treated microsomes were then treated with 50 lM EGCG,
100 lM EGCG, 50 lM S3483 or none (control). Intravesicular
accumulation of radioactive metabolites was detected 6 min after
addition of 10 lM G6P with radio-labeled [14C]G6P tracer. Data are
shown as means + S.E.M., n = 4, *P < 0.05, **P < 0.01 vs. control.vide further evidence for the existence of a microsomal glucose
transporter, which has been disputed for a long time.
3.4. G6Pase activity at various glucose concentrations
The inhibition of glucose eﬄux can lead to the reduction of
G6Pase activity in intact microsomal vesicles if the build-up of
glucose in the lumen acts as an obstacle to G6P hydrolysis – as
reported earlier [28]. The phenomenon was conﬁrmed in the
conditions of our experiments. Glucose reduced the G6Pase
activity both in intact and permeabilized liver microsomes in
a concentration-dependent manner (Fig. 5); and the extent of
inhibition was comparable with that achieved by EGCG in in-Fig. 5. Dependence of G6Pase activity on glucose concentration.
Enzyme activity was measured at 5 mM G6P concentration in intact
(d) and alamethicin-permeabilized (s) liver microsomes (1 mg pro-
tein/ml) in the presence of glucose at the indicated concentrations.
Data are shown as means ± S.E.M. from four experiments.
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higher in the permeabilized microsomes at any glucose concen-
tration, though glucose can equally take eﬀect in the intact and
permeabilized vesicles. The fact that G6Pase latency only de-
creased from 35% to 27% at high glucose concentration is in
accordance with the assumption that G6P transport is rate-
limiting for the overall process.4. Concluding remarks
In summary, our results show that certain tea catechins can
inhibit hepatic G6Pase system directly. The observed 40% inhi-
bition likely contributes to their anti-diabetic, glucose-lowering
eﬀect by measurably reducing hepatic glucose production.
EGCG was administered to a puriﬁed microsomal system in
our experiments; therefore, the phenomenon is independent
of the previously reported G6Pase inhibition, which was due
to a lowered gene expression.
The EGCG concentrations found to be eﬀective in this study
are similar to those (10–100 lM) usually applied in cellular
models to investigate speciﬁc eﬀects of this catechin. Reduced
glucose production and depressed expression of gluconeogenic
enzymes were also found to be most evident at 100 lM EGCG
in hepatoma cells [9,11]. It has been demonstrated in human
pharmacokinetic studies that regular green tea consumption
can only maintain as high as 1–4 lM level of EGCG in blood
plasma [29,30]. However, the concentrations achieved in the
cells and particularly in the hepatic ER have not been mea-
sured. The metabolic eﬀects described in vitro at 10–100 lM
EGCG concentrations [9,11] were in accordance with those ob-
served in vivo after ip injections of pure green tea catechins [7]
or after oral administration of green tea or EGCG [8,10].
These results justify the conditions applied in vitro and suggest
the accumulation of tea ﬂavanols in certain cells well above
plasma concentrations.
The target of EGCG action seems to be the yet-unidentiﬁed
glucose transporter component of the G6Pase system. In addi-
tion to its medical importance, this observation provides fur-
ther experimental evidence for the protein-mediated glucose
transport across the ER membrane. Neither the G6Pase
enzyme nor G6PT was aﬀected while glucose release was hin-
dered and signs of luminal glucose accumulation were detected
in the presence of EGCG. The glucose-sensitivity of G6Pase
further supports the concept that luminal glucose accumula-
tion may be responsible for the inhibitory eﬀect of EGCG.
Since the signaling pathways associated with the ER have
not been reported to be activated or modulated by the luminal
glucose concentration, there is no reason to assume that glu-
cose accumulation in the ER lumen caused by EGCG could
be mechanistically linked to changes in phosphoenolpyruvate
carboxykinase expression and activity. The direct inhibition
of the G6Pase system and the depressed expression of glucone-
ogenic enzymes can independently, yet synergistically reduce
hepatic glucose production.
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